-transparent.png){kind=logo}
(E)-5-(2-Bromovinyl)-2'-deoxyuridine (BVDU) is a highly selective inhibitor of herpes simplex virus-1 (HSV-1). A cell line (LH-1) expressing the HSV thymidine kinase (TK) gene is extremely sensitive to BVDU, whereas the parent line that expresses the cellular TK is resistant to BVDU. A TK-deficient derivative cell line (LMTK(-] which expresses neither the cellular nor viral TK was also extremely sensitive to BVDU. This suggests that the thymidine analog, BVDU, can be phosphorylated in thymidine kinase-deficient cells by pathways other than the cellular or HSV-encoded thymidine kinase.
Related Publications
G Bubley, and
C Crumpacker, and
E De Clercq, and
L Schnipper
May 2001,
Cancer gene therapy,
G Bubley, and
C Crumpacker, and
E De Clercq, and
L Schnipper
January 1985,
Nucleic acids symposium series,
G Bubley, and
C Crumpacker, and
E De Clercq, and
L Schnipper
June 1989,
Methods and findings in experimental and clinical pharmacology,
G Bubley, and
C Crumpacker, and
E De Clercq, and
L Schnipper
January 1991,
Intervirology,
G Bubley, and
C Crumpacker, and
E De Clercq, and
L Schnipper
July 1994,
The Journal of general virology,
G Bubley, and
C Crumpacker, and
E De Clercq, and
L Schnipper
December 1985,
Molecular pharmacology,
G Bubley, and
C Crumpacker, and
E De Clercq, and
L Schnipper
April 1995,
Acta virologica,
G Bubley, and
C Crumpacker, and
E De Clercq, and
L Schnipper
May 1984,
Antimicrobial agents and chemotherapy,
G Bubley, and
C Crumpacker, and
E De Clercq, and
L Schnipper
January 1982,
The Journal of infectious diseases,
G Bubley, and
C Crumpacker, and
E De Clercq, and
L Schnipper
April 1987,
Molecular pharmacology,
